ConductScience.org, home

Paper40596117

Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA.

Virga A and 18 others. Sci Rep, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA. Papers, record 40596117. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40596117

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA.
PubMed
Journal
Sci Rep
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2025-07-04
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Virga AAlessandra
2Urbini MMilena
3Polano MMaurizio
4Petracci EElisabetta
5Tedaldi GGianluca
6Gurioli GGiorgia
7Marisi GGiorgia
8Angeli DDavide
9Ambrosini-Spaltro AAndrea
10De Luca GGiovanni
11Cangini IIlaria
12Zampiga VValentina
13Cenacchi GGiovanna
14Toffoli GGiuseppe
15Casadei CChiara
16Cursano MCMaria Concetta
17Conteduca VVincenza
18De Giorgi UUgo
19Ulivi PPaola

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Whole Genome SequencingMajor topic
MutationMajor topic
Prostatic Neoplasms, Castration-ResistantMajor topic
Circulating Tumor DNAMajor topic
Prostatic NeoplasmsMajor topic
DNA RepairMajor topic
DNA, NeoplasmMajor topic
Recombinational DNA RepairMajor topic
Humans
Male
Aged
Middle Aged
DNA Mutational Analysis
Liquid Biopsy
Aged, 80 and over

Source PubMed

Download CSV of topics

References66

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134753780The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA.Clin Cancer Res2022https://conductscience.org/library/papers/34753780PubMed
231068988Epidemiology of Prostate Cancer.World J Oncol2019https://conductscience.org/library/papers/31068988PubMed
335020204Cancer statistics, 2022.CA Cancer J Clin2022https://conductscience.org/library/papers/35020204PubMed
433538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
516234520Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study.J Clin Oncol2005https://conductscience.org/library/papers/16234520PubMed
633487630Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.Exp Mol Med2021https://conductscience.org/library/papers/33487630PubMed
732220891Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.Clin Cancer Res2020https://conductscience.org/library/papers/32220891PubMed
827433846Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.N Engl J Med2016https://conductscience.org/library/papers/27433846PubMed
930553611Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.Eur Urol2019https://conductscience.org/library/papers/30553611PubMed
1032955174Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.N Engl J Med2020https://conductscience.org/library/papers/32955174PubMed
1140107449Effects of exercise on inflammation, circulating tumor cells, and circulating tumor DNA in colorectal cancer.J Sport Health Sci2025https://conductscience.org/library/papers/40107449PubMed
1236059000Accumulation of copy number alterations and clinical progression across advanced prostate cancer.Genome Med2022https://conductscience.org/library/papers/36059000PubMed
1329109393Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.Nat Commun2017https://conductscience.org/library/papers/29109393PubMed
1435091440Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).Clin Cancer Res2022https://conductscience.org/library/papers/35091440PubMed
1532461654The mutational constraint spectrum quantified from variation in 141,456 humans.Nature2020https://conductscience.org/library/papers/32461654PubMed
1638384439Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study.Eur Urol Open Sci2024https://conductscience.org/library/papers/38384439PubMed
1728446639Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.Mol Cancer Ther2017https://conductscience.org/library/papers/28446639PubMed
1837538150Cell-free DNA in the management of prostate cancer: Current status and future prospective.Asian J Urol2023https://conductscience.org/library/papers/37538150PubMed
1938418825Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.Nat Commun2024https://conductscience.org/library/papers/38418825PubMed
2038201592Clinical Biofluid Assays for Prostate Cancer.Cancers (Basel)2023https://conductscience.org/library/papers/38201592PubMed

See all 66 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42489928Towards implementation of precision medicine biomarkers in early detection and prognostication of prostate cancer.Cancer Metastasis Rev2026https://conductscience.org/library/papers/42489928PubMed
41347816Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers (Review).Int J Oncol2026https://conductscience.org/library/papers/41347816PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
PARP1142PubTator's text mininghttps://conductscience.org/library/genes/142

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40596117

GET https://conductscience.org/api/papers/v1/40596117/references?page=2